Tag Car-T

Blocking ANT2 rewires T cell metabolism, boosting activation, cytokine release, and tumor control — a promising strategy for next-generation immunotherapy....

A groundbreaking first-in-human study published in Cell (2025) demonstrates the effectiveness of QN-139b, an allogeneic, iPSC-derived dual CD19/BCMA CAR-NK cell therapy, in reversing severe fibrosis and autoimmune markers in a patient with treatment-resistant systemic sclerosis. The therapy safely d...

A landmark Nature Medicine study revealed exceptional long-term outcomes, exceeding 15 years, for GD2-directed CAR-T cell therapy in neuroblastoma, a challenging pediatric cancer. The research demonstrated sustained remissions, including one patient disease-free for over 18 years, and prolonged dise...

A recent breakthrough in treating autoimmune diseases was reported in Nature on October 4, 2024, marking the first successful therapy using donor cells to send autoimmune disorders into remission. The therapy involves bioengineered T cells from healthy donors, modified using CRISPR technology, which...